(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.84%.
Organon & Co's revenue in 2026 is $6,163,000,000.On average, 9 Wall Street analysts forecast OGN's revenue for 2026 to be $1,629,175,747,848, with the lowest OGN revenue forecast at $1,545,143,472,008, and the highest OGN revenue forecast at $1,710,844,615,930. On average, 9 Wall Street analysts forecast OGN's revenue for 2027 to be $1,653,335,027,152, with the lowest OGN revenue forecast at $1,541,467,059,940, and the highest OGN revenue forecast at $1,775,707,028,844.
In 2028, OGN is forecast to generate $1,664,889,465,080 in revenue, with the lowest revenue forecast at $1,534,902,038,390 and the highest revenue forecast at $1,796,715,097,804.